Latest Unilife Corp (UNIS) Headlines Unilife to
Post# of 21
Posted On: 03/13/2014 3:47:41 AM
Latest Unilife Corp (UNIS) Headlines
Unilife to Present at the Barclays Global Healthcare Conference on March 13th
PR Newswire - Wed Mar 05, 7:00AM CST
Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS), today announced that its Chairman and CEO, Alan Shortall, will present at the Barclays Global Healthcare Conference in Miami at 09:00 a.m. ET on Thursday, March 13, 2014.
10-K: API TECHNOLOGIES CORP.
Edgar Online - Wed Feb 12, 3:42PM CST
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Sport Chalet Recommends Activities For Couples In Pursuit Of Adventure
PR Newswire - Tue Feb 11, 2:13PM CST
Valentine's Day is upon us and everyone is looking for a way to get closer to that special someone. A recent survey conducted by premier specialty sporting goods retailer Sport Chalet found that 95 percent of consumers are more likely to try a new fitness activity if they have a partner to do it with. To help motivate couples to try something new, this Valentine's Day Sport Chalet is encouraging consumers to explore an activity that either builds camaraderie or promotes healthy competition.
Global Prefilled Syringes Market to 2019: Glass Based and Plastic Based Analysis
M2 - Tue Feb 11, 10:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/lz4k3l/prefilled) has announced the addition of the "Global Prefilled Syringes Market to 2019: Glass Based and Plastic Based Analysis" report to their offering. The market for glass prefilled syringes is expected to lose some of its share at the end of the forecast period, which will be eaten up by the market for plastic syringes that will grow at a CAGR of 25% from 2013 to 2019. Prefilled syringes represent one of the fastest growing segments among the injectable drug delivery devices market. This is mainly due to the various advantages associated with the use of prefilled syringes such as ease of administration, reduced risk of cross contamination, less overfill and ease of handling. The two major segments described in this study are glass-based and plastic-based prefilled syringes. Each of these segments has been analyzed on the basis of their current and future market size in terms of USD million and market volume in terms of million units, considering the macro and micro environmental factors. In addition, the compounded annual growth rate (CAGR) of the overall market and the above segments has also been provided in the report for the forecast period 2013 to 2019, considering 2012 as the base year. Rapid growth in the biologics market, technical advances in the sector and rising preference for self-administration using prefilled syringes, autoinjectors and pen injectors are the major factors driving growth of the global market for prefilled syringes. Currently more than 60% of the drugs under clinical development are biologics and are likely to be approved for parenteral administration. This is because most of the biologics including monoclonal antibodies, vaccines and anticoagulants, are large molecules which need to be administered via parenteral route to achieve the desired therapeutic effect. Likewise, technical advances related with siliconization and needlestick safety and prevention are also expected to drive growth of the market for prefilled syringes. Geographically, the market for prefilled syringes has been classified into four regions namely North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each of these regions along with CAGR has also been provided in the report. A detailed qualitative analysis of the major market dynamics such as drivers, restraints and opportunities, along with Porter's five forces analysis and market attractiveness analysis are discussed in the market overview section of the report. The study also suggests a list of recommendations that is likely to help manufacturers in decision making process. Scope of the Report Segment - Glass Prefilled Syringes Market -- By Revenue (USD Million) -- By Volume (Million units) - Plastic Prefilled Syringes Market -- By Revenue (USD Million) -- By Volume (Million units) Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Prefilled Syringes Market Overview Chapter 4 Global Prefilled Syringes Market Revenue (USD Million) and Volume (Million Units), by Segment, 2011 - 2019 Chapter 5 Global Prefilled Syringes Market Revenue (USD Million) and Volume (Million Units), by Geography, 2011 - 2019 Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles - Baxter International, Inc - Becton, Dickinson & Company - Bespak - Gerresheimer AG - Nipro Corporation - Schott AG - Stevanato Group - Unilife Corporation - Vetter Pharma International GmbH - West Pharmaceutical Services, Inc - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/lz4k3l/prefilled
McLaughlin to join Scripps as VP of news
PR Newswire - Tue Feb 11, 9:50AM CST
The E.W. Scripps Company (NYSE: SSP) has hired industry veteran Sean McLaughlin as its vice president of news, effective March 6.
SynCo Bio Partners Expands Live Microbial Product Experience
PR Newswire - Tue Feb 11, 8:00AM CST
SynCo's live microbial track record, GMP scale-up and commercial manufacturing capabilities will facilitate the advancement of Advaxis' ADXS-HPV program -
Unilife to Participate in the 2014 Annual Leerink Swann Global Healthcare Conference
PR Newswire - Mon Feb 10, 7:00AM CST
Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS), today announced that its Chairman and CEO, Alan Shortall will present at the Leerink Swann Global Healthcare Conference in New York at 1:50 p.m. EST on Thursday, February 13, 2014 (Friday, February 14th at 5:50 a.m. AEDT).
Hot Stock: Unilife, Shares Drop 8.1% (UNIS)
Comtex SmarTrend(R) - Tue Feb 04, 10:12AM CST
Unilife (NASDAQ:UNIS) is one of today's worst performing low-priced stocks, down 8.1% to $3.87 on 1.1x average daily volume. Unilife has traded 1.4 million shares thus far today, vs. average volume of 1.2 million shares per day. The stock has underperformed the Dow (-8.1% to the Dow's 0.2%) and underperformed the S&P 500 (-8.1% to the S&P's 0.4%) during today's trading.
Unilife Corporation Announces Financial Results For Fiscal Year 2014 Second Quarter
PR Newswire - Mon Feb 03, 3:05PM CST
Unilife Corporation ("Unilife" or "Company") (NASDAQ:UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended December 31, 2013, (the second quarter of Fiscal Year 2014).
Unilife Corporation To Announce Financial Results For Fiscal Year 2014 Second Quarter On Monday, February 3, 2014
PR Newswire - Wed Jan 29, 7:00AM CST
Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS) announced today that it intends to release its financial results for the fiscal 2014 second quarter ended December 31, 2013 after market trading ends on Monday, February 3, 2014.
Unilife Announces Dismissal of Shareholder Class Action Lawsuit
PR Newswire - Thu Jan 23, 11:25AM CST
Unilife Corporation ("Unilife") (NASDAQ: UNIS, ASX: UNS) announced today that a recent shareholder class action lawsuit against the Company and certain corporate officers in the United States District Court for the Middle District of Pennsylvania alleging violations of federal securities laws was voluntarily dismissed by the plaintiff.
2013 Report on the International North America Injectable Drug Delivery Market - Forecasts to 2017
M2 - Thu Jan 23, 5:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/3brffr/north_america) has announced the addition of the "2013 Report on the International North America Injectable Drug Delivery Market - Forecasts to 2017" report to their offering. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices. The major markets covered in this report are United States and Canada. The United States accounted for the largest market of the North American injectable drug delivery technologies market in the year 2012. However, Canada is expected to witness high growth due to growing prevalence of diabetes and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, increase in approval of injectable formulation and device, favorable reimbursement and rise in injectable cosmetic treatments. This research report categorizes and analyzes the North American injectable drug delivery technologies market under two broad segments - devices and formulations. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Injectable Drug Delivery Devices Technologies Market 5 Injectable Drug Delivery Formulation Technologies Market 6 Injectable Drug Delivery Technologies Market,By Therapeutic Applications 7 Geographic Analysis 8 Competitive Landscape 9 Company Profiles Companies Mentioned: - Antares Pharma - Baxter International - Becton, Dickinson and Company - Eli Lilly And Company - Hospira - Novo Nordisk - Sanofi - Unilife Corporation - West Pharmaceutical Services - Zogenix. For more information visit http://www.researchandmarkets.com/research/3b...th_america
Unilife Shares Up 36.9% Since SmarTrend's Buy Recommendation (UNIS)
Comtex SmarTrend(R) - Fri Jan 17, 9:58AM CST
SmarTrend identified an Uptrend for Unilife (NASDAQ:UNIS) on November 20th, 2013 at $3.81. In approximately 2 months, Unilife has returned 36.93% as of today's recent price of $5.21.
5 Stocks Under $10 Set to Soar
at The Street - Thu Jan 16, 12:57PM CST
These under-$10 stocks look ready to break out and trade higher from current levels.
2013 Report on the International Injectable Drug Delivery Market - Includes Forecasts to 2017
M2 - Thu Jan 02, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/5fj7x3/injectable_drug) has announced the addition of the "2013 Report on the International Injectable Drug Delivery Market - Includes Forecasts to 2017" report to their offering. The injectable drug delivery market is technology driven and is marked by the 'Threat of Obsolescence' wherein technologies as well as its adoption by patients changes very rapidly. The industry has seen a shift in paradigm and is now skewed toward self-injection devices that not only cure serious illnesses but also have fewer serious side effects. The market for injectable drug delivery includes devices and formulations. Traditionally, injectable devices were primarily designed for delivery of insulin and human growth hormones. However, due to technological advancements they are currently being used as combination therapies for the delivery of a wide variety of drug classes such as anticholinergic, hematopoietic, dopamine agonists, parathyroid hormones, reproductive hormones, serotonin antagonists, sympathomimetic and immune modulators. Self injection devices including auto injectors and pen injectors are the fastest growing segments in the injectable drug delivery market. In recent years, the uptake and adoption of self-injection devices such as auto and pen injectors has grown substantially. This is due to the benefits it offers over conventional injection devices. Self-injection devices ensure better patient adherence to treatment due to decrease risk of missed injection or drug discontinuation, and reduced healthcare cost as costly hospital visits are curtailed. This has ignited the interest of device manufacturers who are in turn incessantly coming up with new variants of self-injection devices with advanced technological features. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Injectable Drug Delivery Devices Technologies Market 5 Global Injectable Drug Delivery Formulation Technologies Market 6 Global Injectable Drug Delivery Technologies Market, By Therapeutic Applications 7 Geographic Analysis 8 Competitive Landscape 9 Company Profiles Companies Mentioned: - Alkermes - Antares Pharma - Baxter International - Becton, Dickinson And Company - Bespak Europe - Crossject - Elcam Medical - Eli Lilly And Company - Gerresheimer - Haselmeier - Injex Pharma - Novo Nordisk - Owen Mumford - Sanofi - Schott - Shl Group - Terumo Corporation - Unilife Corporation - Vetter Pharma-Fertigung - West Pharmaceutical Services - Ypsomed Holding - Zogenix For more information visit http://www.researchandmarkets.com/research/5f...table_drug
Healthcare Companies Announce Study Results, Acquisitions and Company Updates - Research Report on Sirona Dental Systems, Ligand Pharmaceuticals, Genomic Health, Unilife, and Sykes
PR Newswire - Tue Dec 24, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Sirona Dental Systems Inc. (NASDAQ: SIRO), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), Genomic Health Inc. (NASDAQ: GHDX), Unilife Corporation (NASDAQ: UNIS), and Stryker Corporation, Incorporated (NYSE: SYK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Market Expert Opinion: Baxter Intl., Unilife, CareFusion, and Mindray Medical Intl.
PR Newswire - Mon Dec 23, 7:00AM CST
On Friday, December 20, 2013, the U.S. equity market edged higher as the S&P 500 ended the day at 1,818.32, up 0.48%; the Dow Jones Industrial Average closed at 16,221.14, up 0.26%; and the NASDAQ Composite finished at 4,104.74, up 1.15%. The S&P 500 Health Care Sector Index edged 0.45% higher to close the day at 635.97; and the S&P 500 Health Care Equipment & Supplies Industry Index closed 682.28, up 0.36%. The S&P 500 Health Care Equipment & Supplies Industry Index has gained 2.58% in the previous three trading sessions and 4.90% in the last three months, compared to a gain of 2.10% and 6.84% in the S&P 500 during the respective periods. The major movers in the industry included Baxter International Inc. (NYSE: BAX), Unilife Corporation (NASDAQ: UNIS), CareFusion Corporation (NYSE: CFN), and Mindray Medical International Ltd (NYSE: MR). All these companies are tracked by AAAResearchReports.com. Free technical research on BAX, UNIS, CFN, and MR can be downloaded upon signing up at:
Zuoan Fashion Limited Announces Third Quarter 2013 Financial Results
PR Newswire - Fri Dec 20, 5:30AM CST
Zuoan Fashion Limited (NYSE: ZA) ("Zuoan" or the "Company"), a leading design-driven fashion casual menswear company in China, today announced its financial results for the third quarter ended September 30, 2013.
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of Unilife Corporation of Upcoming Deadline
Business Wire - Mon Dec 16, 1:41PM CST
Rigrodsky & Long, P.A.:
Unilife Signs Agreement with Global Pharmaceutical Company Seeking to Use Ocu-Ject(TM) to Deliver a Drug into the Eye
PR Newswire - Mon Dec 16, 8:30AM CST
Unilife Corporation ("Unilife") (NASDAQ: UNIS, ASX: UNS) today announced the signing of an agreement with a global pharmaceutical company seeking to use the Unilife Ocu-ject(TM) ocular drug delivery system to deliver a target injectable therapy into the eye.
Unilife to Present at the Barclays Global Healthcare Conference on March 13th
PR Newswire - Wed Mar 05, 7:00AM CST
Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS), today announced that its Chairman and CEO, Alan Shortall, will present at the Barclays Global Healthcare Conference in Miami at 09:00 a.m. ET on Thursday, March 13, 2014.
10-K: API TECHNOLOGIES CORP.
Edgar Online - Wed Feb 12, 3:42PM CST
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Sport Chalet Recommends Activities For Couples In Pursuit Of Adventure
PR Newswire - Tue Feb 11, 2:13PM CST
Valentine's Day is upon us and everyone is looking for a way to get closer to that special someone. A recent survey conducted by premier specialty sporting goods retailer Sport Chalet found that 95 percent of consumers are more likely to try a new fitness activity if they have a partner to do it with. To help motivate couples to try something new, this Valentine's Day Sport Chalet is encouraging consumers to explore an activity that either builds camaraderie or promotes healthy competition.
Global Prefilled Syringes Market to 2019: Glass Based and Plastic Based Analysis
M2 - Tue Feb 11, 10:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/lz4k3l/prefilled) has announced the addition of the "Global Prefilled Syringes Market to 2019: Glass Based and Plastic Based Analysis" report to their offering. The market for glass prefilled syringes is expected to lose some of its share at the end of the forecast period, which will be eaten up by the market for plastic syringes that will grow at a CAGR of 25% from 2013 to 2019. Prefilled syringes represent one of the fastest growing segments among the injectable drug delivery devices market. This is mainly due to the various advantages associated with the use of prefilled syringes such as ease of administration, reduced risk of cross contamination, less overfill and ease of handling. The two major segments described in this study are glass-based and plastic-based prefilled syringes. Each of these segments has been analyzed on the basis of their current and future market size in terms of USD million and market volume in terms of million units, considering the macro and micro environmental factors. In addition, the compounded annual growth rate (CAGR) of the overall market and the above segments has also been provided in the report for the forecast period 2013 to 2019, considering 2012 as the base year. Rapid growth in the biologics market, technical advances in the sector and rising preference for self-administration using prefilled syringes, autoinjectors and pen injectors are the major factors driving growth of the global market for prefilled syringes. Currently more than 60% of the drugs under clinical development are biologics and are likely to be approved for parenteral administration. This is because most of the biologics including monoclonal antibodies, vaccines and anticoagulants, are large molecules which need to be administered via parenteral route to achieve the desired therapeutic effect. Likewise, technical advances related with siliconization and needlestick safety and prevention are also expected to drive growth of the market for prefilled syringes. Geographically, the market for prefilled syringes has been classified into four regions namely North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each of these regions along with CAGR has also been provided in the report. A detailed qualitative analysis of the major market dynamics such as drivers, restraints and opportunities, along with Porter's five forces analysis and market attractiveness analysis are discussed in the market overview section of the report. The study also suggests a list of recommendations that is likely to help manufacturers in decision making process. Scope of the Report Segment - Glass Prefilled Syringes Market -- By Revenue (USD Million) -- By Volume (Million units) - Plastic Prefilled Syringes Market -- By Revenue (USD Million) -- By Volume (Million units) Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Prefilled Syringes Market Overview Chapter 4 Global Prefilled Syringes Market Revenue (USD Million) and Volume (Million Units), by Segment, 2011 - 2019 Chapter 5 Global Prefilled Syringes Market Revenue (USD Million) and Volume (Million Units), by Geography, 2011 - 2019 Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles - Baxter International, Inc - Becton, Dickinson & Company - Bespak - Gerresheimer AG - Nipro Corporation - Schott AG - Stevanato Group - Unilife Corporation - Vetter Pharma International GmbH - West Pharmaceutical Services, Inc - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/lz4k3l/prefilled
McLaughlin to join Scripps as VP of news
PR Newswire - Tue Feb 11, 9:50AM CST
The E.W. Scripps Company (NYSE: SSP) has hired industry veteran Sean McLaughlin as its vice president of news, effective March 6.
SynCo Bio Partners Expands Live Microbial Product Experience
PR Newswire - Tue Feb 11, 8:00AM CST
SynCo's live microbial track record, GMP scale-up and commercial manufacturing capabilities will facilitate the advancement of Advaxis' ADXS-HPV program -
Unilife to Participate in the 2014 Annual Leerink Swann Global Healthcare Conference
PR Newswire - Mon Feb 10, 7:00AM CST
Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS), today announced that its Chairman and CEO, Alan Shortall will present at the Leerink Swann Global Healthcare Conference in New York at 1:50 p.m. EST on Thursday, February 13, 2014 (Friday, February 14th at 5:50 a.m. AEDT).
Hot Stock: Unilife, Shares Drop 8.1% (UNIS)
Comtex SmarTrend(R) - Tue Feb 04, 10:12AM CST
Unilife (NASDAQ:UNIS) is one of today's worst performing low-priced stocks, down 8.1% to $3.87 on 1.1x average daily volume. Unilife has traded 1.4 million shares thus far today, vs. average volume of 1.2 million shares per day. The stock has underperformed the Dow (-8.1% to the Dow's 0.2%) and underperformed the S&P 500 (-8.1% to the S&P's 0.4%) during today's trading.
Unilife Corporation Announces Financial Results For Fiscal Year 2014 Second Quarter
PR Newswire - Mon Feb 03, 3:05PM CST
Unilife Corporation ("Unilife" or "Company") (NASDAQ:UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended December 31, 2013, (the second quarter of Fiscal Year 2014).
Unilife Corporation To Announce Financial Results For Fiscal Year 2014 Second Quarter On Monday, February 3, 2014
PR Newswire - Wed Jan 29, 7:00AM CST
Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS) announced today that it intends to release its financial results for the fiscal 2014 second quarter ended December 31, 2013 after market trading ends on Monday, February 3, 2014.
Unilife Announces Dismissal of Shareholder Class Action Lawsuit
PR Newswire - Thu Jan 23, 11:25AM CST
Unilife Corporation ("Unilife") (NASDAQ: UNIS, ASX: UNS) announced today that a recent shareholder class action lawsuit against the Company and certain corporate officers in the United States District Court for the Middle District of Pennsylvania alleging violations of federal securities laws was voluntarily dismissed by the plaintiff.
2013 Report on the International North America Injectable Drug Delivery Market - Forecasts to 2017
M2 - Thu Jan 23, 5:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/3brffr/north_america) has announced the addition of the "2013 Report on the International North America Injectable Drug Delivery Market - Forecasts to 2017" report to their offering. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices. The major markets covered in this report are United States and Canada. The United States accounted for the largest market of the North American injectable drug delivery technologies market in the year 2012. However, Canada is expected to witness high growth due to growing prevalence of diabetes and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, increase in approval of injectable formulation and device, favorable reimbursement and rise in injectable cosmetic treatments. This research report categorizes and analyzes the North American injectable drug delivery technologies market under two broad segments - devices and formulations. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Injectable Drug Delivery Devices Technologies Market 5 Injectable Drug Delivery Formulation Technologies Market 6 Injectable Drug Delivery Technologies Market,By Therapeutic Applications 7 Geographic Analysis 8 Competitive Landscape 9 Company Profiles Companies Mentioned: - Antares Pharma - Baxter International - Becton, Dickinson and Company - Eli Lilly And Company - Hospira - Novo Nordisk - Sanofi - Unilife Corporation - West Pharmaceutical Services - Zogenix. For more information visit http://www.researchandmarkets.com/research/3b...th_america
Unilife Shares Up 36.9% Since SmarTrend's Buy Recommendation (UNIS)
Comtex SmarTrend(R) - Fri Jan 17, 9:58AM CST
SmarTrend identified an Uptrend for Unilife (NASDAQ:UNIS) on November 20th, 2013 at $3.81. In approximately 2 months, Unilife has returned 36.93% as of today's recent price of $5.21.
5 Stocks Under $10 Set to Soar
at The Street - Thu Jan 16, 12:57PM CST
These under-$10 stocks look ready to break out and trade higher from current levels.
2013 Report on the International Injectable Drug Delivery Market - Includes Forecasts to 2017
M2 - Thu Jan 02, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/5fj7x3/injectable_drug) has announced the addition of the "2013 Report on the International Injectable Drug Delivery Market - Includes Forecasts to 2017" report to their offering. The injectable drug delivery market is technology driven and is marked by the 'Threat of Obsolescence' wherein technologies as well as its adoption by patients changes very rapidly. The industry has seen a shift in paradigm and is now skewed toward self-injection devices that not only cure serious illnesses but also have fewer serious side effects. The market for injectable drug delivery includes devices and formulations. Traditionally, injectable devices were primarily designed for delivery of insulin and human growth hormones. However, due to technological advancements they are currently being used as combination therapies for the delivery of a wide variety of drug classes such as anticholinergic, hematopoietic, dopamine agonists, parathyroid hormones, reproductive hormones, serotonin antagonists, sympathomimetic and immune modulators. Self injection devices including auto injectors and pen injectors are the fastest growing segments in the injectable drug delivery market. In recent years, the uptake and adoption of self-injection devices such as auto and pen injectors has grown substantially. This is due to the benefits it offers over conventional injection devices. Self-injection devices ensure better patient adherence to treatment due to decrease risk of missed injection or drug discontinuation, and reduced healthcare cost as costly hospital visits are curtailed. This has ignited the interest of device manufacturers who are in turn incessantly coming up with new variants of self-injection devices with advanced technological features. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Injectable Drug Delivery Devices Technologies Market 5 Global Injectable Drug Delivery Formulation Technologies Market 6 Global Injectable Drug Delivery Technologies Market, By Therapeutic Applications 7 Geographic Analysis 8 Competitive Landscape 9 Company Profiles Companies Mentioned: - Alkermes - Antares Pharma - Baxter International - Becton, Dickinson And Company - Bespak Europe - Crossject - Elcam Medical - Eli Lilly And Company - Gerresheimer - Haselmeier - Injex Pharma - Novo Nordisk - Owen Mumford - Sanofi - Schott - Shl Group - Terumo Corporation - Unilife Corporation - Vetter Pharma-Fertigung - West Pharmaceutical Services - Ypsomed Holding - Zogenix For more information visit http://www.researchandmarkets.com/research/5f...table_drug
Healthcare Companies Announce Study Results, Acquisitions and Company Updates - Research Report on Sirona Dental Systems, Ligand Pharmaceuticals, Genomic Health, Unilife, and Sykes
PR Newswire - Tue Dec 24, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Sirona Dental Systems Inc. (NASDAQ: SIRO), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), Genomic Health Inc. (NASDAQ: GHDX), Unilife Corporation (NASDAQ: UNIS), and Stryker Corporation, Incorporated (NYSE: SYK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Market Expert Opinion: Baxter Intl., Unilife, CareFusion, and Mindray Medical Intl.
PR Newswire - Mon Dec 23, 7:00AM CST
On Friday, December 20, 2013, the U.S. equity market edged higher as the S&P 500 ended the day at 1,818.32, up 0.48%; the Dow Jones Industrial Average closed at 16,221.14, up 0.26%; and the NASDAQ Composite finished at 4,104.74, up 1.15%. The S&P 500 Health Care Sector Index edged 0.45% higher to close the day at 635.97; and the S&P 500 Health Care Equipment & Supplies Industry Index closed 682.28, up 0.36%. The S&P 500 Health Care Equipment & Supplies Industry Index has gained 2.58% in the previous three trading sessions and 4.90% in the last three months, compared to a gain of 2.10% and 6.84% in the S&P 500 during the respective periods. The major movers in the industry included Baxter International Inc. (NYSE: BAX), Unilife Corporation (NASDAQ: UNIS), CareFusion Corporation (NYSE: CFN), and Mindray Medical International Ltd (NYSE: MR). All these companies are tracked by AAAResearchReports.com. Free technical research on BAX, UNIS, CFN, and MR can be downloaded upon signing up at:
Zuoan Fashion Limited Announces Third Quarter 2013 Financial Results
PR Newswire - Fri Dec 20, 5:30AM CST
Zuoan Fashion Limited (NYSE: ZA) ("Zuoan" or the "Company"), a leading design-driven fashion casual menswear company in China, today announced its financial results for the third quarter ended September 30, 2013.
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of Unilife Corporation of Upcoming Deadline
Business Wire - Mon Dec 16, 1:41PM CST
Rigrodsky & Long, P.A.:
Unilife Signs Agreement with Global Pharmaceutical Company Seeking to Use Ocu-Ject(TM) to Deliver a Drug into the Eye
PR Newswire - Mon Dec 16, 8:30AM CST
Unilife Corporation ("Unilife") (NASDAQ: UNIS, ASX: UNS) today announced the signing of an agreement with a global pharmaceutical company seeking to use the Unilife Ocu-ject(TM) ocular drug delivery system to deliver a target injectable therapy into the eye.
(0)
(0)Unilife Corporation (UNIS) Stock Research Links
Scroll down for more posts ▼